Theoretically, our study found that GOLPH3 high cells exhibited higher sensitivity to gefitinib treatment, indicating the great potential that the GOLPH3 high GBM patients may benefit from anti‐EGFR therapy. This evidence concerns the gene EGFR and glioblastoma.